New safety warnings about the risk of ileus have been added to all GLP-1 receptor agonists following a TGA investigation into local reports of the gastrointestinal event.

Last week, the regulator said it had updated the product information for semaglutide (Ozempic), dulaglutide (Trulicity) and tirzepatide (Mounjaro) to include intestinal obstruction and ileus as adverse events.